How similar are generic and branded tigecycline's clinical outcomes?

How do clinical outcomes compare between generic and branded tigecycline?

Generic and branded versions of tigecycline produce similar clinical outcomes in published studies. A direct comparison of 131 patients found cure rates of 80.9% with the generic form and 79.0% with the branded form, with no statistical difference.

How do side effects differ between generic and branded versions?

Side effects occur at similar rates. In the same study, adverse events affected 51.5% of patients receiving the generic drug and 50.8% of those receiving the branded version. Nausea, vomiting, and the reported number of deaths were also comparable.

Why are companies challenging tigecycline patents?

Patent disputes center around formulation and stability improvements. Companies such as Fresenius Kabi, Fresenius Polypharm, and Mylan filed Paragraph IV challenges against Pfizer’s patents covering tigecycline formulations. These challenges led to litigation and settlement agreements that resulted in early generic entry.

When does the main tigecycline patent expire?

The main patent held by Pfizer for tigecycline expires on 9 November 2023. The earliest date for an authorized generic entry was set for 1 June 2023 under settlement agreements. [1]

What company makes the branded version?

The branded version of tigecycline is made by Pfizer under the name Tygacil.